The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
In the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) received 3 somewhat bullish and 2 indifferent analyst ratings. The average price target is $77.8, representing an upside from the current price of $52.165. The average price target has increased by 50.57% over the past month.
June 06, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical received 3 somewhat bullish and 2 indifferent analyst ratings in the last quarter, with an average price target of $77.8, up 50.57% in the past month.
The average price target for Ultragenyx Pharmaceutical has increased by 50.57% over the past month, indicating a positive sentiment among analysts. With 3 somewhat bullish and 2 indifferent ratings, the stock is likely to experience an upward trend in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100